Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma

Gene Therapy

Volumn 22, Issue 7, 2015, Pages 578-590

  Bosnjak, M ^a   Dolinsek, T ^a   Cemazar, M ^a,b   Kranjc, S ^a   Blagus, T ^a   Markelc, B ^a   Stimac, M ^a   Zavrsnik, J ^c   Kamensek, U ^a   Heller, L ^d   Bouquet, C ^e   Turk, B ^c   Sersa, G ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY OF PRIMORSKA   (Slovenia)

^c JO EF STEFAN INSTITUTE   (Slovenia)

^d OLD DOMINION UNIVERSITY   (United States)

^e BioAlliance Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGIOGENIC METARGIDIN PEPTIDE; INTEGRIN; INTEGRIN RECEPTOR; UNCLASSIFIED DRUG; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC GENE THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFICACY; DRUG MECHANISM; ELECTROPORATION; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; IN VITRO STUDY; IN VIVO STUDY; INVESTIGATIVE PROCEDURES; MELANOMA B16; MELANOMA CELL; METASTASIS POTENTIAL; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE THERAPY; GENE VECTOR; GENETICS; MELANOMA, EXPERIMENTAL; METABOLISM; PROCEDURES; THERAPEUTIC USE; TUMOR CELL LINE;

MURINAE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPORATION; ENDOTHELIAL CELLS; GENETIC THERAPY; GENETIC VECTORS; INTEGRINS; MELANOMA, EXPERIMENTAL; MICE; PEPTIDES;

EID: 84934272198     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.26     Document Type: Article

References (34)

1. Heller LC, Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010; 10: 312-317.
2. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-5903.
3. Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010; 10: 300-311.
4. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999; 222: 124-138.
5. Trochon-Joseph V, Martel-Renoir D, Mir LM, Thomaidis A, Opolon P, Connault E et al. Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res 2004; 64: 2062-2069.
6. Daugimont L, Vandermeulen G, Defresne F, Bouzin C, Mir LM, Bouquet C et al. Antitumoral and antimetastatic effect of antiangiogenic plasmids in B16 melanoma: higher efficiency of the recombinant disintegrin domain of ADAM 15. Eur J Pharm Biopharm 2011; 78: 314-319.
7. Bosnjak M, Prosen L, Dolinsek T, Blagus T, Markelc B, Cemazar M et al. Biological properties of melanoma and endothelial cells after plasmid AMEP gene electrotransfer depend on integrin quantity on cells. J Membr Biol 2013; 246: 803-819.
8. Spanggaard I, Snoj M, Cavalcanti A, Bouquet C, Sersa G, Robert C et al. Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. Hum Gene Ther Clin Dev 2013; 24: 99-107.
9. Tesic N, Cemazar M. In vitro targeted gene electrotransfer to endothelial cells with plasmid DNA containing human endothelin-1 promoter. J Membr Biol 2013; 246: 783-791.
10. Bosnjak M, Lorente BC, Pogacar Z, Makovsek V, Cemazar M. Different incubation times of cells after gene electrotransfer in fetal bovine serum affect cell. viability but not transfection efficiency. J Membr Biol 2014; 247: 421-428.
11. Tevz G, Kranjc S, Cemazar M, Kamensek U, Coer A, Krzan M et al. Controlled systemic release of interleukin-12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas. J Gene Med 2009; 11: 1125-1137.
12. Mir LM, Banoun H, Paoletti C. Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res 1988; 175: 15-25.
13. Mir LM, Orlowski S, Belehradek Jr. J, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 1991; 27: 68-72.
14. Sersa G, Cemazar M, Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res 1995; 55: 3450-3455.
15. Cemazar M, Miklavcic D, Sersa G. Intrinsic sensitivity of tumor cells to bleomycin as an indicator of tumor response to electrochemotherapy. Jpn J Cancer Res 1998; 89: 328-333.
16. Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs 2000; 11: 201-208.
17. Sersa G, Miklavcic D. Electrochemotherapy of tumours. J Vis Exp 2008; 15: 1038.
18. Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M et al. Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radiol Oncol 2012; 46: 302-311.
19. Teissie J, Escoffre JM, Paganin A, Chabot S, Bellard E, Wasungu L et al. Drug delivery by electropulsation: Recent developments in oncology. Int J Pharm 2012; 423: 3-6.
20. Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B et al. Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol 2014; 110: 320-327.
21. Miklavcic D, Mali B, Kos B, Heller R, Sersa G. Electrochemotherapy: from the drawing board into medical practice. Biomed Eng Online 2014; 13: 29.
22. Mali B, Miklavcic D, Campana LG, Cemazar M, Sersa G, Snoj M et al. Tumor size and effectiveness of electrochemotherapy. Radiol Oncol 2013; 47: 32-41.
23. Rols MP, Delteil C, Golzio M, Dumond P, Cros S, Teissie J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998; 16: 168-171.
24. Jaroszeski MJ, Gilbert R, Nicolau C, Heller R. In vivo gene delivery by electroporation. Adv Drug Deliv Rev 1999; 35: 131-137.
25. Golzio M, Rols MP, Teissie J. In vitro and in vivo electric field-mediated permeabilization, gene transfer, and expression. Methods 2004; 33: 126-135.
26. Vidic S, Markelc B, Sersa G, Coer A, Kamensek U, Tevz G et al. MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo. Cancer Gene Ther 2010; 17: 409-419.
27. Chabot S, Pelofy S, Paganin-Gioanni A, Teissie J, Golzio M. Electrotransfer of RNAi-based oligonucleotides for oncology. Anticancer Res 2011; 31: 4083-4089.
28. Dolinsek T, Markelc B, Sersa G, Coer A, Stimac M, Lavrencak J et al. Multiple delivery of siRNA against endoglin into murine mammary adenocarcinoma prevents angiogenesis and delays tumor growth. PLoS One 2013; 8: e58723.
29. Kamensek U, Sersa G, Cemazar M. Evaluation of p21 promoter for interleukin 12 radiation induced transcriptional targeting in a mouse tumor model. Mol Cancer 2013; 12: 136.
30. Prosen L, Markelc B, Dolinsek T, Music B, Cemazar M, Sersa G. Mcam silencing with RNA interference using magnetofection has antitumor effect in murine melanoma. Mol Ther Nucleic Acids 2014; 3: e205.
31. Crokart N, Danhier F, Daugimont L, Goncalves N, Jordan BF, Gregoire V et al. Potentiation of radiotherapy by a localized antiangiogenic gene therapy. Radiother Oncol 2013; 107: 252-258.
32. Robinson SD, Hodivala-Dilke KM. The role of beta3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 2011; 23: 630-637.
33. Niemisto A, Dunmire V, Yli-Harja O, Zhang W, Shmulevich I. Robust quantification of in vitro angiogenesis through image analysis. IEEE Trans Med Imaging 2005; 24: 549-553.
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.